Watch a 1-hour webinar from the 2018 Antibody Engineering & Therapeutics Digital Week titled, “Emerging Technologies for Finding Rare Antibodies,” featuring scientists from Berkeley Lights and Teva Pharmaceuticals.
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.